Telemark Asset Management LLC lifted its position in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 25.0% during the 4th quarter, HoldingsChannel reports. The firm owned 500,000 shares of the company’s stock after buying an additional 100,000 shares during the period. Telemark Asset Management LLC’s holdings in Cellebrite DI were worth $11,015,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in shares of Cellebrite DI by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock worth $7,202,000 after purchasing an additional 75,092 shares during the period. Two Sigma Advisers LP increased its holdings in shares of Cellebrite DI by 9.8% in the third quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock worth $22,584,000 after purchasing an additional 120,000 shares during the period. Harbor Capital Advisors Inc. increased its holdings in shares of Cellebrite DI by 65.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock worth $3,473,000 after purchasing an additional 62,320 shares during the period. State Street Corp increased its holdings in shares of Cellebrite DI by 7.3% in the third quarter. State Street Corp now owns 443,700 shares of the company’s stock worth $7,472,000 after purchasing an additional 30,052 shares during the period. Finally, New York State Common Retirement Fund increased its stake in Cellebrite DI by 2.6% in the fourth quarter. New York State Common Retirement Fund now owns 189,599 shares of the company’s stock valued at $4,177,000 after acquiring an additional 4,838 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.
Cellebrite DI Trading Up 2.3 %
Shares of NASDAQ:CLBT opened at $17.62 on Thursday. The stock’s 50-day moving average price is $21.58 and its 200-day moving average price is $19.70. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The stock has a market capitalization of $3.63 billion, a P/E ratio of -12.68, a price-to-earnings-growth ratio of 4.27 and a beta of 1.53.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on CLBT. JPMorgan Chase & Co. increased their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Lake Street Capital increased their target price on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of Cellebrite DI in a research note on Monday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $23.43.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
- Five stocks we like better than Cellebrite DI
- Trading Stocks: RSI and Why it’s Useful
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Stock Sentiment Analysis: How it Works
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- How Technical Indicators Can Help You Find Oversold Stocks
- Why Energy Transfer Belongs on Your Watchlist
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.